ID   KIT_HUMAN               Reviewed;         976 AA.
AC   P10721; Q99662; Q9UM99;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   02-NOV-2010, entry version 139.
DE   RecName: Full=Mast/stem cell growth factor receptor;
DE            Short=SCFR;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Kit;
DE   AltName: Full=Tyrosine-protein kinase Kit;
DE   AltName: CD_antigen=CD117;
DE   Flags: Precursor;
GN   Name=KIT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal brain, and Term placenta;
RX   MEDLINE=88111521; PubMed=2448137;
RA   Yarden Y., Kuang W.-J., Yang-Feng T., Coussens L., Munemitsu S.,
RA   Dull T.J., Chen E., Schlessinger J., Francke U., Ullrich A.;
RT   "Human proto-oncogene c-kit: a new cell surface receptor tyrosine
RT   kinase for an unidentified ligand.";
RL   EMBO J. 6:3341-3351(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS
RP   1 AND 2).
RX   MEDLINE=93064697; PubMed=1279499;
RA   Giebel L.B., Strunk K.M., Holmes S.A., Spritz R.A.;
RT   "Organization and nucleotide sequence of the human KIT (mast/stem cell
RT   growth factor receptor) proto-oncogene.";
RL   Oncogene 7:2207-2217(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=97179223; PubMed=9027509; DOI=10.1006/geno.1996.4482;
RA   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V.,
RA   Hu W.X., Galibert F.;
RT   "Sequence analysis of two genomic regions containing the KIT and the
RT   FMS receptor tyrosine kinase genes.";
RL   Genomics 39:216-226(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=7506248;
RA   Yamamoto K., Tojo A., Aoki N., Shibuya M.;
RT   "Characterization of the promoter region of the human c-kit proto-
RT   oncogene.";
RL   Jpn. J. Cancer Res. 84:1136-1144(1993).
RN   [7]
RP   INTERACTION WITH PTPRU.
RX   PubMed=10397721;
RA   Taniguchi Y., London R., Schinkmann K., Jiang S., Avraham H.;
RT   "The receptor protein tyrosine phosphatase, PTP-RO, is upregulated
RT   during megakaryocyte differentiation and is associated with the c-Kit
RT   receptor.";
RL   Blood 94:539-549(1999).
RN   [8]
RP   INTERACTION WITH MPDZ, CHARACTERIZATION OF VARIANT VAL-816, AND
RP   MUTAGENESIS OF LYS-623.
RX   MEDLINE=20472558; PubMed=11018522; DOI=10.1016/S0014-5793(00)02036-6;
RA   Mancini A., Koch A., Stefan M., Niemann H., Tamura T.;
RT   "The direct association of the multiple PDZ domain containing proteins
RT   (MUPP-1) with the human c-Kit C-terminus is regulated by tyrosine
RT   kinase activity.";
RL   FEBS Lett. 482:54-58(2000).
RN   [9]
RP   INTERACTION WITH APS, AND MUTAGENESIS OF ILE-571 AND LEU-939.
RX   MEDLINE=22510236; PubMed=12444928; DOI=10.1042/BJ20020716;
RA   Wollberg P., Lennartsson J., Gottfridsson E., Yoshimura A.,
RA   Ronnstrand L.;
RT   "The adapter protein APS associates with the multifunctional docking
RT   sites Tyr-568 and Tyr-936 in c-Kit.";
RL   Biochem. J. 370:1033-1038(2003).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-130, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-936, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-959, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   VARIANT PIEBALDISM LYS-583.
RX   MEDLINE=92291284; PubMed=1376329; DOI=10.1172/JCI115772;
RA   Fleischman R.A.;
RT   "Human piebald trait resulting from a dominant negative mutant allele
RT   of the c-kit membrane receptor gene.";
RL   J. Clin. Invest. 89:1713-1717(1992).
RN   [14]
RP   VARIANT PIEBALDISM LEU-584.
RX   MEDLINE=92133600; PubMed=1370874;
RA   Spritz R.A., Giebel L.B., Holmes S.A.;
RT   "Dominant negative and loss of function mutations of the c-kit
RT   (mast/stem cell growth factor receptor) proto-oncogene in human
RT   piebaldism.";
RL   Am. J. Hum. Genet. 50:261-269(1992).
RN   [15]
RP   VARIANT PIEBALDISM ARG-664.
RX   MEDLINE=92020918; PubMed=1717985; DOI=10.1073/pnas.88.19.8696;
RA   Giebel L.B., Spritz R.A.;
RT   "Mutation of the KIT (mast/stem cell growth factor receptor)
RT   protooncogene in human piebaldism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8696-8699(1991).
RN   [16]
RP   VARIANT MAST CELL LEUKEMIA VAL-816.
RX   MEDLINE=94013473; PubMed=7691885; DOI=10.1172/JCI116761;
RA   Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H.,
RA   Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y.,
RA   Matsuzawa Y., Kitamura Y., Kanakura Y.;
RT   "Identification of mutations in the coding sequence of the proto-
RT   oncogene c-kit in a human mast cell leukemia cell line causing ligand-
RT   independent activation of c-kit product.";
RL   J. Clin. Invest. 92:1736-1744(1993).
RN   [17]
RP   VARIANTS PIEBALDISM GLY-791 AND VAL-812.
RX   MEDLINE=93322624; PubMed=7687267; DOI=10.1111/1523-1747.ep12358440;
RA   Spritz R.A., Holmes S.A., Itin P., Kuester W.;
RT   "Novel mutations of the KIT (mast/stem cell growth factor receptor)
RT   proto-oncogene in human piebaldism.";
RL   J. Invest. Dermatol. 101:22-25(1993).
RN   [18]
RP   VARIANT PIEBALDISM 893-GLU--PRO-896 DEL.
RX   MEDLINE=96287384; PubMed=8680409; DOI=10.1002/humu.1380060409;
RA   Riva P., Milani N., Gandolfi P., Larizza L.;
RT   "A 12-bp deletion (7818del12) in the c-kit protooncogene in a large
RT   Italian kindred with piebaldism.";
RL   Hum. Mutat. 6:343-345(1995).
RN   [19]
RP   VARIANT MAST CELL DISEASE GLY-820.
RX   PubMed=9029028; DOI=10.1046/j.1365-2141.1997.d01-2042.x;
RA   Pignon J.-M., Giraudier S., Duquesnoy P., Jouault H., Imbert M.,
RA   Vainchenker W., Vernant J.-P., Tulliez M.;
RT   "A new c-kit mutation in a case of aggressive mast cell disease.";
RL   Br. J. Haematol. 96:374-376(1997).
RN   [20]
RP   VARIANT PIEBALDISM GLY-796.
RX   PubMed=9450866;
RX   DOI=10.1002/(SICI)1096-8628(19980106)75:1<101::AID-AJMG20>3.0.CO;2-P;
RA   Spritz R.A., Beighton P.;
RT   "Piebaldism with deafness: molecular evidence for an expanded
RT   syndrome.";
RL   Am. J. Med. Genet. 75:101-103(1998).
RN   [21]
RP   VARIANT ACUTE MYELOID LEUKEMIA TYR-816.
RX   PubMed=9657776;
RA   Beghini A., Larizza L., Cairoli R., Morra E.;
RT   "c-kit activating mutations and mast cell proliferation in human
RT   leukemia.";
RL   Blood 92:701-702(1998).
RN   [22]
RP   VARIANT PIEBALDISM PRO-847.
RX   PubMed=9699740; DOI=10.1046/j.1523-1747.1998.00269.x;
RA   Nomura K., Hatayama I., Narita T., Kaneko T., Shiraishi M.;
RT   "A novel KIT gene missense mutation in a Japanese family with
RT   piebaldism.";
RL   J. Invest. Dermatol. 111:337-338(1998).
RN   [23]
RP   VARIANT GIST VAL-559 DEL.
RX   MEDLINE=98361155; PubMed=9697690; DOI=10.1038/1209;
RA   Nishida T., Hirota S., Taniguchi M., Hashimoto K., Isozaki K.,
RA   Nakamura H., Kanakura Y., Tanaka T., Takabayashi A., Matsuda H.,
RA   Kitamura Y.;
RT   "Familial gastrointestinal stromal tumours with germline mutation of
RT   the KIT gene.";
RL   Nat. Genet. 19:323-324(1998).
RN   [24]
RP   VARIANTS GIST ILE-550; 550-LYS--LYS-558 DEL; 551-PRO--VAL-555 DEL;
RP   ASP-559 AND 559-VAL-VAL-560 DEL.
RX   PubMed=9438854; DOI=10.1126/science.279.5350.577;
RA   Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T.,
RA   Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M.,
RA   Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y.,
RA   Kitamura Y.;
RT   "Gain-of-function mutations of c-kit in human gastrointestinal stromal
RT   tumors.";
RL   Science 279:577-580(1998).
RN   [25]
RP   VARIANT HIS-816, AND CHARACTERIZATION OF VARIANT HIS-816.
RX   PubMed=10362788;
RA   Tian Q., Frierson H.F. Jr., Krystal G.W., Moskaluk C.A.;
RT   "Activating c-kit gene mutations in human germ cell tumors.";
RL   Am. J. Pathol. 154:1643-1647(1999).
RN   [26]
RP   VARIANTS MASTOCYTOSIS VAL-816; PHE-816; TYR-816 AND LYS-839, AND
RP   CHARACTERIZATION OF VARIANTS MASTOCYTOSIS VAL-816; PHE-816; TYR-816
RP   AND LYS-839.
RX   PubMed=9990072; DOI=10.1073/pnas.96.4.1609;
RA   Longley B.J. Jr., Metcalfe D.D., Tharp M., Wang X., Tyrrell L.,
RA   Lu S.-Z., Heitjan D., Ma Y.;
RT   "Activating and dominant inactivating c-KIT catalytic domain mutations
RT   in distinct clinical forms of human mastocytosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1609-1614(1999).
RN   [27]
RP   VARIANTS PIEBALDISM CYS-584; ARG-601 AND PRO-656.
RX   PubMed=11074500;
RX   DOI=10.1002/1096-8628(20001106)95:1<79::AID-AJMG16>3.0.CO;2-4;
RA   Syrris P., Malik N.M., Murday V.A., Patton M.A., Carter N.D.,
RA   Hughes H.E., Metcalfe K.;
RT   "Three novel mutations of the proto-oncogene KIT cause human
RT   piebaldism.";
RL   Am. J. Med. Genet. 95:79-81(2000).
RN   [28]
RP   VARIANT GIST ALA-559.
RX   PubMed=11505412;
RX   DOI=10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D;
RA   Beghini A., Tibiletti M.G., Roversi G., Chiaravalli A.M., Serio G.,
RA   Capella C., Larizza L.;
RT   "Germline mutation in the juxtamembrane domain of the kit gene in a
RT   family with gastrointestinal stromal tumors and urticaria
RT   pigmentosa.";
RL   Cancer 92:657-662(2001).
RN   [29]
RP   VARIANT GIST 550-LYS--LYS-558 DEL.
RX   PubMed=15824741; DOI=10.1038/sj.onc.1208587;
RA   Chen L.L., Sabripour M., Wu E.F., Prieto V.G., Fuller G.N.,
RA   Frazier M.L.;
RT   "A mutation-created novel intra-exonic pre-mRNA splice site causes
RT   constitutive activation of KIT in human gastrointestinal stromal
RT   tumors.";
RL   Oncogene 24:4271-4280(2005).
RN   [30]
RP   VARIANTS TYR-816; LYS-822 AND PRO-829.
RX   PubMed=16175573; DOI=10.1002/gcc.20265;
RA   Bignell G., Smith R., Hunter C., Stephens P., Davies H., Greenman C.,
RA   Teague J., Butler A., Edkins S., Stevens C., O'meara S., Parker A.,
RA   Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J.,
RA   Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K.,
RA   Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R.,
RA   Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R.,
RA   Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A.,
RA   West S., Widaa S., Yates A., Gillis A.J.M., Stoop H.J.,
RA   van Gurp R.J.H.L.M., Oosterhuis J.W., Looijenga L.H.J., Futreal P.A.,
RA   Wooster R., Stratton M.R.;
RT   "Sequence analysis of the protein kinase gene family in human
RT   testicular germ-cell tumors of adolescents and adults.";
RL   Genes Chromosomes Cancer 45:42-46(2006).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-532; LEU-541; SER-691; ASN-715;
RP   ASN-737; TRP-804; TYR-816; LYS-822 AND PRO-829.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: This is the receptor for stem cell factor (mast cell
CC       growth factor). It has a tyrosine-protein kinase activity. Binding
CC       of the ligands leads to the autophosphorylation of KIT and its
CC       association with substrates such as phosphatidylinositol 3-kinase
CC       (Pi3K).
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts with APS. Interacts with MPDZ (via the tenth
CC       PDZ domain). Interacts with PTPRU.
CC   -!- INTERACTION:
CC       P62993:GRB2; NbExp=2; IntAct=EBI-1379503, EBI-401755;
CC       P21583:KITLG; NbExp=1; IntAct=EBI-1379503, EBI-1379527;
CC       P35235:Ptpn11 (xeno); NbExp=2; IntAct=EBI-1379503, EBI-397236;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-1379503, EBI-2264500;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P10721-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P10721-2; Sequence=VSP_038385;
CC   -!- DISEASE: Defects in KIT are a cause of piebaldism [MIM:172800].
CC       Piebaldism is an autosomal dominant genetic developmental
CC       abnormality of pigmentation characterized by congenital patches of
CC       white skin and hair that lack melanocytes.
CC   -!- DISEASE: Defects in KIT are a cause of gastrointestinal stromal
CC       tumor (GIST) [MIM:606764].
CC   -!- DISEASE: Defects in KIT have been associated with testicular
CC       tumors (TEST) [MIM:273300]. A common solid malignancy in males.
CC       Germ cell tumors of the testis constitute 95% of all testicular
CC       neoplasms.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/KITID127.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/KIT";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD117 entry;
CC       URL="http://en.wikipedia.org/wiki/CD117";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06182; CAA29548.1; -; mRNA.
DR   EMBL; X69301; CAA49159.1; -; Genomic_DNA.
DR   EMBL; X69302; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69303; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69304; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69305; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69306; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69307; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69308; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69309; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69310; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69311; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69312; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69313; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69314; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69315; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69316; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; U63834; AAC50968.1; -; Genomic_DNA.
DR   EMBL; U63834; AAC50969.1; -; Genomic_DNA.
DR   EMBL; AK304031; BAG64945.1; -; mRNA.
DR   EMBL; AC006552; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092545; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S67773; AAB29529.1; -; Genomic_DNA.
DR   IPI; IPI00022296; -.
DR   IPI; IPI00848233; -.
DR   PIR; S01426; TVHUKT.
DR   RefSeq; NP_000213.1; -.
DR   RefSeq; NP_001087241.1; -.
DR   UniGene; Hs.479754; -.
DR   PDB; 1PKG; X-ray; 2.90 A; A/B=549-931.
DR   PDB; 1QZJ; Model; -; A=576-932.
DR   PDB; 1QZK; Model; -; A=576-932.
DR   PDB; 1R01; Model; -; A=576-932.
DR   PDB; 1T45; X-ray; 1.90 A; A=547-935.
DR   PDB; 1T46; X-ray; 1.60 A; A=565-935.
DR   PDB; 2E9W; X-ray; 3.50 A; A/B=26-514.
DR   PDB; 2EC8; X-ray; 3.00 A; A=1-519.
DR   PDB; 2VIF; X-ray; 1.45 A; P=564-574.
DR   PDB; 3G0E; X-ray; 1.60 A; A=544-935.
DR   PDB; 3G0F; X-ray; 2.60 A; A/B=544-935.
DR   PDBsum; 1PKG; -.
DR   PDBsum; 1QZJ; -.
DR   PDBsum; 1QZK; -.
DR   PDBsum; 1R01; -.
DR   PDBsum; 1T45; -.
DR   PDBsum; 1T46; -.
DR   PDBsum; 2E9W; -.
DR   PDBsum; 2EC8; -.
DR   PDBsum; 2VIF; -.
DR   PDBsum; 3G0E; -.
DR   PDBsum; 3G0F; -.
DR   ProteinModelPortal; P10721; -.
DR   DIP; DIP-1055N; -.
DR   IntAct; P10721; 15.
DR   STRING; P10721; -.
DR   PhosphoSite; P10721; -.
DR   PRIDE; P10721; -.
DR   Ensembl; ENST00000288135; ENSP00000288135; ENSG00000157404.
DR   GeneID; 3815; -.
DR   KEGG; hsa:3815; -.
DR   UCSC; uc010igr.1; human.
DR   CTD; 3815; -.
DR   GeneCards; GC04P055439; -.
DR   H-InvDB; HIX0031398; -.
DR   HGNC; HGNC:6342; KIT.
DR   HPA; CAB003288; -.
DR   HPA; HPA004471; -.
DR   MIM; 164920; gene.
DR   MIM; 172800; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 606764; phenotype.
DR   Orphanet; 98850; Aggressive systemic mastocytosis.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 98848; Indolent systemic mastocytosis.
DR   Orphanet; 98851; Mast cell leukemia.
DR   Orphanet; 98292; Mastocytosis.
DR   Orphanet; 2884; Piebaldism.
DR   Orphanet; 2467; Systemic mastocytosis.
DR   Orphanet; 98849; Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease.
DR   PharmGKB; PA30128; -.
DR   eggNOG; prNOG15493; -.
DR   HOGENOM; HBG445154; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P10721; -.
DR   OMA; THGRITK; -.
DR   OrthoDB; EOG98WFN0; -.
DR   PhylomeDB; P10721; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   NextBio; 14995; -.
DR   ArrayExpress; P10721; -.
DR   Bgee; P10721; -.
DR   CleanEx; HS_KIT; -.
DR   Genevestigator; P10721; -.
DR   GermOnline; ENSG00000157404; Homo sapiens.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase ...; TAS:ProtInc.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kin...; IEA:InterPro.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020730; Tyr_kinase_mast_cell_GF_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR016243; Tyr_prot_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_prot_kinase_rcpt_3_CS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 5.
DR   PANTHER; PTHR23256:SF238; Tyr_kinase_mast_cell_GF_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     25       Potential.
FT   CHAIN        26    976       Mast/stem cell growth factor receptor.
FT                                /FTId=PRO_0000016754.
FT   TOPO_DOM     26    524       Extracellular (Potential).
FT   TRANSMEM    525    545       Helical; (Potential).
FT   TOPO_DOM    546    976       Cytoplasmic (Potential).
FT   DOMAIN       27    112       Ig-like C2-type 1.
FT   DOMAIN      121    205       Ig-like C2-type 2.
FT   DOMAIN      212    308       Ig-like C2-type 3.
FT   DOMAIN      317    410       Ig-like C2-type 4.
FT   DOMAIN      413    507       Ig-like C2-type 5.
FT   DOMAIN      589    937       Protein kinase.
FT   NP_BIND     595    603       ATP (By similarity).
FT   ACT_SITE    792    792       Proton acceptor (By similarity).
FT   BINDING     623    623       ATP (By similarity).
FT   SITE        568    568       Interaction with APS.
FT   SITE        936    936       Interaction with APS.
FT   MOD_RES     568    568       Phosphotyrosine (By similarity).
FT   MOD_RES     570    570       Phosphotyrosine (By similarity).
FT   MOD_RES     703    703       Phosphotyrosine (By similarity).
FT   MOD_RES     823    823       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     936    936       Phosphotyrosine.
FT   MOD_RES     959    959       Phosphoserine.
FT   CARBOHYD    130    130       N-linked (GlcNAc...).
FT   CARBOHYD    145    145       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    283    283       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    293    293       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    300    300       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    320    320       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    352    352       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    367    367       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    463    463       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    486    486       N-linked (GlcNAc...) (Potential).
FT   DISULFID     58     97       By similarity.
FT   DISULFID    151    183       By similarity.
FT   DISULFID    233    290       By similarity.
FT   DISULFID    428    491       By similarity.
FT   VAR_SEQ     510    513       Missing (in isoform 2).
FT                                /FTId=VSP_038385.
FT   VARIANT     532    532       V -> I (in dbSNP:rs55792975).
FT                                /FTId=VAR_042021.
FT   VARIANT     541    541       M -> L (in dbSNP:rs3822214).
FT                                /FTId=VAR_042022.
FT   VARIANT     541    541       M -> V (in dbSNP:rs3822214).
FT                                /FTId=VAR_061289.
FT   VARIANT     550    558       Missing (in GIST; somatic mutation).
FT                                /FTId=VAR_033124.
FT   VARIANT     550    550       K -> I (in GIST; somatic mutation;
FT                                dbSNP:rs28933968).
FT                                /FTId=VAR_033123.
FT   VARIANT     551    555       Missing (in GIST; somatic mutation).
FT                                /FTId=VAR_033125.
FT   VARIANT     559    560       Missing (in GIST; somatic mutation).
FT                                /FTId=VAR_033128.
FT   VARIANT     559    559       V -> A (in GIST).
FT                                /FTId=VAR_033126.
FT   VARIANT     559    559       V -> D (in GIST; somatic mutation).
FT                                /FTId=VAR_033127.
FT   VARIANT     559    559       Missing (in GIST).
FT                                /FTId=VAR_007965.
FT   VARIANT     583    583       E -> K (in piebaldism).
FT                                /FTId=VAR_004104.
FT   VARIANT     584    584       F -> C (in piebaldism; dbSNP:rs28933371).
FT                                /FTId=VAR_033129.
FT   VARIANT     584    584       F -> L (in piebaldism).
FT                                /FTId=VAR_004105.
FT   VARIANT     601    601       G -> R (in piebaldism).
FT                                /FTId=VAR_033130.
FT   VARIANT     656    656       L -> P (in piebaldism).
FT                                /FTId=VAR_033131.
FT   VARIANT     664    664       G -> R (in piebaldism).
FT                                /FTId=VAR_004106.
FT   VARIANT     691    691       C -> S (in dbSNP:rs35200131).
FT                                /FTId=VAR_042023.
FT   VARIANT     715    715       S -> N (in dbSNP:rs56094246).
FT                                /FTId=VAR_042024.
FT   VARIANT     737    737       D -> N (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042025.
FT   VARIANT     791    791       R -> G (in piebaldism).
FT                                /FTId=VAR_004107.
FT   VARIANT     796    796       R -> G (in piebaldism; with sensorineural
FT                                deafness).
FT                                /FTId=VAR_033132.
FT   VARIANT     804    804       R -> W (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042026.
FT   VARIANT     812    812       G -> V (in piebaldism).
FT                                /FTId=VAR_004108.
FT   VARIANT     816    816       D -> F (in mastocytosis; requires 2
FT                                nucleotide substitutions; somatic
FT                                mutation; constitutively activated).
FT                                /FTId=VAR_033133.
FT   VARIANT     816    816       D -> H (in a testicular tumor; seminoma;
FT                                somatic mutation; constitutively
FT                                activated; dbSNP:rs28933969).
FT                                /FTId=VAR_033134.
FT   VARIANT     816    816       D -> V (in mast cell leukemia and
FT                                mastocytosis; somatic mutation;
FT                                constitutively activated; loss of
FT                                interaction with MPDZ).
FT                                /FTId=VAR_004109.
FT   VARIANT     816    816       D -> Y (in acute myeloid leukemia,
FT                                mastocytosis and a germ cell tumor of the
FT                                testis; somatic mutation; constitutively
FT                                activated).
FT                                /FTId=VAR_023828.
FT   VARIANT     820    820       D -> G (in mast cell disease; systemic).
FT                                /FTId=VAR_033135.
FT   VARIANT     822    822       N -> K (in a germ cell tumor of the
FT                                testis; somatic mutation).
FT                                /FTId=VAR_023829.
FT   VARIANT     829    829       A -> P (in a germ cell tumor of the
FT                                testis; somatic mutation).
FT                                /FTId=VAR_023830.
FT   VARIANT     839    839       E -> K (in mastocytosis; somatic
FT                                mutation; dominant negative mutation;
FT                                loss of autophosphorylation).
FT                                /FTId=VAR_033136.
FT   VARIANT     847    847       T -> P (in piebaldism).
FT                                /FTId=VAR_033137.
FT   VARIANT     893    896       Missing (in piebaldism; severe).
FT                                /FTId=VAR_004110.
FT   MUTAGEN     571    571       I->A: Reduction in APS binding. Abolishes
FT                                APS binding; when associated with A-939.
FT   MUTAGEN     623    623       K->M: Stronger interaction with MPDZ.
FT   MUTAGEN     939    939       L->A: Reduction in APS binding. Abolishes
FT                                APS binding; when associated with A-571.
FT   STRAND      556    560
FT   HELIX       580    582
FT   HELIX       586    588
FT   STRAND      589    597
FT   STRAND      599    613
FT   STRAND      617    625
FT   HELIX       631    647
FT   STRAND      656    660
FT   STRAND      662    665
FT   STRAND      667    671
FT   HELIX       678    690
FT   HELIX       766    785
FT   HELIX       795    797
FT   STRAND      798    801
FT   HELIX       802    804
FT   STRAND      805    808
FT   HELIX       812    814
FT   HELIX       817    819
FT   STRAND      823    831
FT   HELIX       833    835
FT   HELIX       838    843
FT   HELIX       848    863
FT   HELIX       877    885
FT   HELIX       897    906
FT   HELIX       911    913
FT   HELIX       917    930
FT   TURN        931    933
SQ   SEQUENCE   976 AA;  109865 MW;  81B0CD76817F3454 CRC64;
     MRGARGAWDF LCVLLLLLRV QTGSSQPSVS PGEPSPPSIH PGKSDLIVRV GDEIRLLCTD
     PGFVKWTFEI LDETNENKQN EWITEKAEAT NTGKYTCTNK HGLSNSIYVF VRDPAKLFLV
     DRSLYGKEDN DTLVRCPLTD PEVTNYSLKG CQGKPLPKDL RFIPDPKAGI MIKSVKRAYH
     RLCLHCSVDQ EGKSVLSEKF ILKVRPAFKA VPVVSVSKAS YLLREGEEFT VTCTIKDVSS
     SVYSTWKREN SQTKLQEKYN SWHHGDFNYE RQATLTISSA RVNDSGVFMC YANNTFGSAN
     VTTTLEVVDK GFINIFPMIN TTVFVNDGEN VDLIVEYEAF PKPEHQQWIY MNRTFTDKWE
     DYPKSENESN IRYVSELHLT RLKGTEGGTY TFLVSNSDVN AAIAFNVYVN TKPEILTYDR
     LVNGMLQCVA AGFPEPTIDW YFCPGTEQRC SASVLPVDVQ TLNSSGPPFG KLVVQSSIDS
     SAFKHNGTVE CKAYNDVGKT SAYFNFAFKG NNKEQIHPHT LFTPLLIGFV IVAGMMCIIV
     MILTYKYLQK PMYEVQWKVV EEINGNNYVY IDPTQLPYDH KWEFPRNRLS FGKTLGAGAF
     GKVVEATAYG LIKSDAAMTV AVKMLKPSAH LTEREALMSE LKVLSYLGNH MNIVNLLGAC
     TIGGPTLVIT EYCCYGDLLN FLRRKRDSFI CSKQEDHAEA ALYKNLLHSK ESSCSDSTNE
     YMDMKPGVSY VVPTKADKRR SVRIGSYIER DVTPAIMEDD ELALDLEDLL SFSYQVAKGM
     AFLASKNCIH RDLAARNILL THGRITKICD FGLARDIKND SNYVVKGNAR LPVKWMAPES
     IFNCVYTFES DVWSYGIFLW ELFSLGSSPY PGMPVDSKFY KMIKEGFRML SPEHAPAEMY
     DIMKTCWDAD PLKRPTFKQI VQLIEKQISE STNHIYSNLA NCSPNRQKPV VDHSVRINSV
     GSTASSSQPL LVHDDV
//
